Compare Global E Online Ltd (GLBE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Novo Nordisk A/S — how do they compare? Global E Online Ltd trades at $40.42 (market cap $6.87B), while Novo Nordisk A/S trades at $46.22 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 30.3× Global E Online Ltd's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| GLBE | NVO | |
|---|---|---|
Market Cap | $6.87B | $207.85B |
Sector | Technology | Health |
52-Week High | $42.32 | $63.98 |
52-Week Low | $27.54 | $35.29 |
Enterprise Value | $6.34B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $42.08, up 2.26% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS expectations and raising full-year guidance, driven by 39% revenue growth and expanded EBITDA margins. Analyst consensus is unanimously bullish with a $44.75 price target, reflecting confidence in its e-commerce enablement platform.
The stock offers upside potential from robust growth and strategic acquisitions like Passport, but risks include high valuation multiples (P/E of 61.06) and insider selling. Execution on raised guidance and integration of new logistics capabilities are key to sustaining momentum amid competitive pressures.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
